Loading clinical trials...
Loading clinical trials...
This study will evaluate the safety and tolerability of increasing doses of PF-06840003 in patients with malignant gliomas.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Pfizer
NCT05765812 · Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III
NCT04065776 · Glioma, Pilocytic Astrocytoma, and more
NCT05099003 · Malignant Glioma
NCT05278208 · High Grade Glioma, Meningioma, and more
NCT02800486 · Glioblastoma, Anaplastic Astrocytoma, and more
Ronald Reagan UCLA Medical Center
Los Angeles, California
UCLA Clinical & Translational Research Center
Los Angeles, California
UCLA Oncology Center
Los Angeles, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions